CLCr (mL/min) | N | Median of initial dose (mg/day, range) | Defined initial dose (mg/day) | Developed adverse effects | Developed adverse effects with over defined initial dose |
---|---|---|---|---|---|
>60 | 127 | 150 (25–450) | 150 | 41 (32.3 %) | 1 (2.4 %) |
>30–≤60 | 55 | 75 (25–150) | 75 | 17 (30.9 %) | 8 (47.1 %) |
≤30 | 13 | 50 (25–150) | 25 or 50 | 5 (38.5 %) | 2 (40.0 %) |